Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Prime Medicine’s PM-359?
Prime Medicine is a biotechnology company that develops precision genetic medicines to treat serious genetic diseases. The company’s gene editing technology, Prime Editing, is designed to edit, ...
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Immuneering’s IMM-1-104?
IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing.
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Revolution Medicines’s RMC-9805?
Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. The company’s pipeline products include RMC-6236 an investigational ...
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Alumis’s ESK-001?
ESK-001 is a small molecule commercialized by Alumis, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 9 clinical trials, of which ...
Pharmaceutical Technology20m
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Pharmaceutical Technology20m
Risk adjusted net present value: What is the current valuation of Pfizer’s Ibuzatrelvir?
Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology20m
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
The revenue for Amycretin is expected to reach an annual total of $137 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology20m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-6234?
AZD-6234 is under development for the treatment of obesity. It is administered through subcutaneous and intravenous route. The therapeutic candidate is a long acting amylin analogue. The company ...
Pharmaceutical Technology20m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sipavibart?
The revenue for Sipavibart is expected to reach an annual total of $28 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology22m
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Eloralintide?
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
Pharmaceutical Technology22m
Risk adjusted net present value: What is the current valuation of Alto Neuroscience’s Agomelatine?
Agomelatine is a small molecule commercialized by Alto Neuroscience, with a leading Phase II program in Major Depressive Disorder.
Pharmaceutical Technology26m
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Ulefnersen Sodium?
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.